fasudil has been researched along with Lupus Erythematosus, Systemic in 2 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil treatment significantly improved survival and decreased proteinuria, particularly when treatment was started at 18 weeks." | 1.38 | Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. ( Bhagat, G; Biswas, PS; Gupta, S; Pernis, AB; Song, L; Stirzaker, RA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pernis, AB | 2 |
| Ricker, E | 1 |
| Weng, CH | 1 |
| Rozo, C | 1 |
| Yi, W | 1 |
| Stirzaker, RA | 1 |
| Biswas, PS | 1 |
| Gupta, S | 1 |
| Song, L | 1 |
| Bhagat, G | 1 |
1 review available for fasudil and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Rho Kinases in Autoimmune Diseases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Arthritis, Rheumatoid; Autoimmune Di | 2016 |
1 other study available for fasudil and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antigen-Antibody Compl | 2012 |